Dexmedetomidine for Delirium Prevention in Intensive Care Unit Patients

Abstract

Introduction: Delirium in intensive care unit (ICU) settings increases morbidity, mortality, and healthcare costs. This review examines whether dexmedetomidine, a selective alpha-2 agonist, reduces delirium incidence compared to other sedatives.

Methods: A literature review identified randomized controlled trials comparing dexmedetomidine versus benzodiazepines, propofol, or placebo for sedation in mechanically ventilated adults. Primary outcome was delirium incidence assessed by Confusion Assessment Method for the ICU. Secondary outcomes included ventilator-free days and ICU length of stay.

Results: Nine trials with 2,396 patients were analyzed. Dexmedetomidine reduced delirium risk by 28% compared to benzodiazepines but showed no significant difference versus propofol. Ventilator-free days were similar between dexmedetomidine and propofol groups. Bradycardia and hypotension occurred more frequently with dexmedetomidine, though rarely requiring treatment cessation.

Discussion: The neuroprotective effect of dexmedetomidine may stem from preserved sleep architecture, anti-inflammatory properties, and reduced neuronal apoptosis. The absence of benefit over propofol suggests that avoiding benzodiazepines, rather than choosing a specific agent, is critical. Most trials excluded patients with severe hepatic or renal impairment, limiting applicability.

Conclusions: Dexmedetomidine is superior to benzodiazepines for delirium prevention in mechanically ventilated ICU patients but offers no advantage over propofol. Selection should be guided by hemodynamic tolerance and institutional protocols.